|
市場調査レポート
商品コード
1547935
髄膜炎菌ワクチンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測Global Meningococcal Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
カスタマイズ可能
|
|||||||
| 髄膜炎菌ワクチンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測 |
|
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 222 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
髄膜炎菌ワクチン市場の世界需要は、2023年の55億7,000万米ドルから2032年には約102億8,000万米ドルの市場規模に達すると推定され、調査期間2024～2032年のCAGRは7.05%です。
髄膜炎菌ワクチンは髄膜炎菌疾患の予防に役立ちます。髄膜炎菌性疾患は、髄膜炎菌によって引き起こされます。ワクチンには抗原物質が含まれており、身体の免疫系を高めて抗体を作らせ、この抗体が細菌を攻撃して殺すことで身体を守ります。ワクチンは筋肉に注射するか、皮膚のすぐ下に注射します。髄膜炎菌ワクチンには3種類あります。多糖体ワクチン、結合型ワクチン、タンパク質ベースのワクチンです。
市場力学
髄膜炎菌性髄膜炎の罹患率の増加が市場の成長を促進しています。髄膜炎菌性疾患は致死的となる可能性があり、すべての州で報告可能な状態で世界中で観察されていますが、この疾患の負担が最も大きいのはサハラ以南のアフリカで、西はセネガルから東はエチオピアまで広がっています。様々な臨床試験は、結果を決定するために実行されます。COVID-19を根絶するための候補として、多くの薬やワクチンが同定されています。髄膜炎菌性疾患に対するワクチンであるChAdOx1 nCoV-19もその一つです。このワクチンは、免疫系をプライミングしてコロナウイルスを認識・攻撃させ、T細胞反応を刺激することで作用し、動物実験や初期段階のヒト実験で安全性が確認されており、コロナウイルス版と市場成長に自信を与えています。
調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは髄膜炎菌ワクチンの世界市場における各セグメントを包括的に評価することもできます。髄膜炎菌ワクチン産業の成長と動向は、この調査に全体的なアプローチを記載しています。
市場セグメンテーション
髄膜炎菌ワクチン市場レポートのこのセクションでは、国・地域レベルのセグメントに関する詳細なデータを提供することで、戦略家がそれぞれの製品またはサービスの対象層を特定する上で、今後のビジネス機会を支援します。
地域分析
このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける髄膜炎菌ワクチン市場の現在と将来の需要を強調する地域展望を取り上げます。さらに、本レポートは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。
カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。
目次
第1章 序文
第2章 エグゼクティブサマリー
- 市場のハイライト
- 世界市場スナップショット
第3章 髄膜炎菌ワクチン-産業分析
- イントロダクション-市場力学
- 市場促進要因
- 市場抑制要因
- 市場機会
- 業界動向
- ポーターのファイブフォース分析
- 市場の魅力分析
第4章 バリューチェーン分析
- バリューチェーン分析
- 原材料分析
- 原材料リスト
- 原材料メーカー一覧
- 主要原材料の価格動向
- 潜在的バイヤー一覧
- マーケティングチャネル
- 直接マーケティング
- 間接マーケティング
- マーケティングチャネル発展動向
第5章 髄膜炎菌ワクチンの世界市場分析：タイプ別
- タイプ別概要
- 実績データと予測データ
- タイプ別分析
- 二価
- 四価
- その他
第6章 髄膜炎菌ワクチンの世界市場分析：ブランド別
- ブランド別概要
- 実績データと予測データ
- ブランド別分析
- メナクトラ
- メンベオ
- ニメンリックス
- トルメンバ
- ベクセロ
- その他
第7章 髄膜炎菌ワクチンの世界市場分析：年齢層別
- 年齢層別概要
- 実績データと予測データ
- 年齢層別分析
- 乳児（0～2歳）
- 小児と成人（2歳以上）
第8章 髄膜炎菌ワクチンの世界市場分析：血清型別
- 血清型別概要
- 実績データと予測データ
- 血清型別分析
- A血清型
- B血清型
- C血清型
- W-135血清型
- Y血清型
第9章 髄膜炎菌ワクチンの世界市場分析：流通チャネル別
- 流通チャネル別概要
- 実績データと予測データ
- 流通チャネル別分析
- 民間
- 公共
第10章 髄膜炎菌ワクチンの世界市場分析：地域別
- 地域別展望
- イントロダクション
- 北米売上分析
- 概要、実績と予測
- 北米：セグメント別
- 北米：国別
- 米国
- カナダ
- メキシコ
- 欧州売上分析
- 概要、実績と予測
- 欧州：セグメント別
- 欧州：国別
- 英国
- フランス
- ドイツ
- イタリア
- ロシア
- その他の欧州
- アジア太平洋売上分析
- 概要、実績と予測
- アジア太平洋：セグメント別
- アジア太平洋：国別
- 中国
- インド
- 日本
- 韓国
- オーストラリア
- 東南アジア
- その他のアジア太平洋
- ラテンアメリカ売上分析
- 概要、実績と予測
- ラテンアメリカ：セグメント別
- ラテンアメリカ：国別
- ブラジル
- アルゼンチン
- ペルー
- チリ
- その他のラテンアメリカ
- 中東・アフリカ売上分析
- 概要、実績と予測
- 中東・アフリカ：セグメント別
- 中東・アフリカ：国別一覧
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他の中東・アフリカ
第11章 髄膜炎菌ワクチン企業の競合情勢
- 髄膜炎菌ワクチン市場競合
- パートナーシップ/提携/協定
- 合併・買収
- 新製品上市
- その他の開発
第12章 企業プロファイル
- 上位企業の市場シェア分析
- 市場集中度
- Pfizer Inc.
- Sanofi
- Serum Institute Of India Ltd.
- GSK Plc.
- Merck & Co. Inc.
- Walvax Biotechnology Co. Ltd
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Type (USD MN)
- Bivalent Market Sales By Geography (USD MN)
- Quadrivalent Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Analysis By Brand (USD MN)
- Menactra Market Sales By Geography (USD MN)
- Menveo Market Sales By Geography (USD MN)
- Nimenrix Market Sales By Geography (USD MN)
- Trumenba Market Sales By Geography (USD MN)
- Bexsero Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Analysis By Age Group (USD MN)
- Infants (0 to 2 years) Market Sales By Geography (USD MN)
- Children and Adults (2 years & above) Market Sales By Geography (USD MN)
- Analysis By Serotype (USD MN)
- Serotype A Market Sales By Geography (USD MN)
- Serotype B Market Sales By Geography (USD MN)
- Serotype C Market Sales By Geography (USD MN)
- Serotype W-135 Market Sales By Geography (USD MN)
- Serotype Y Market Sales By Geography (USD MN)
- Analysis By Sales Channel (USD MN)
- Private Market Sales By Geography (USD MN)
- Public Market Sales By Geography (USD MN)
- Global Meningococcal Vaccine Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Meningococcal Vaccine Report
- Market Research Process
- Market Research Methodology
- Global Meningococcal Vaccine Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Type
- Market Attractiveness Analysis By Brand
- Market Attractiveness Analysis By Age Group
- Market Attractiveness Analysis By Serotype
- Market Attractiveness Analysis By Sales Channel
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Type (USD MN)
- Bivalent Market Sales By Geography (USD MN)
- Quadrivalent Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Market Analysis By Brand (USD MN)
- Menactra Market Sales By Geography (USD MN)
- Menveo Market Sales By Geography (USD MN)
- Nimenrix Market Sales By Geography (USD MN)
- Trumenba Market Sales By Geography (USD MN)
- Bexsero Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Market Analysis By Age Group (USD MN)
- Infants (0 to 2 years) Market Sales By Geography (USD MN)
- Children and Adults (2 years & above) Market Sales By Geography (USD MN)
- Global Market Analysis By Serotype (USD MN)
- Serotype A Market Sales By Geography (USD MN)
- Serotype B Market Sales By Geography (USD MN)
- Serotype C Market Sales By Geography (USD MN)
- Serotype W-135 Market Sales By Geography (USD MN)
- Serotype Y Market Sales By Geography (USD MN)
- Global Market Analysis By Sales Channel (USD MN)
- Private Market Sales By Geography (USD MN)
- Public Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
The global demand for Meningococcal Vaccine Market is presumed to reach the market size of nearly USD 10.28 Billion by 2032 from USD 5.57 Billion in 2023 with a CAGR of 7.05% under the study period 2024-2032.
Meningococcal vaccine helps prevent meningococcal disease. The meningococcal disease is caused by Neisseria meningitides bacteria. The vaccines contain antigens substances that boost the body's immune system and cause it to make antibodies, these antibodies then protect the body by attacking and killing the bacteria. The vaccine is given either by injection into a muscle or just under the skin. There are three types of meningococcal vaccines available: Polysaccharide vaccines, conjugate vaccines, and protein based vaccine.
MARKET DYNAMICS
Growing incidence of meningococcal meningitis is driving the growth of market. Meningococcal disease is potentially fatal, observed worldwide with reportable condition in all states, but the highest burden of the disease is in the sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.Market is predicted to experience new waves in the growth owing to the COVID-19, an emerging an rapidly evolving situation.Scientist across the world are focused on discovering vaccine for coronavirus. Various clinical trials are executed to determine the results. Number of drugs and vaccine is identified as candidate to eradicate COVID-19. ChAdOx1 nCoV-19, vaccine against meningococcal disease is among the one. This vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response and has appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version and market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Meningococcal Vaccine. The growth and trends of Meningococcal Vaccine industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Meningococcal Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Bivalent
- Quadrivalent
- Others
By Brand
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
By Age Group
- Infants (0 to 2 years)
- Children and Adults (2 years & above)
By Serotype
- Serotype A
- Serotype B
- Serotype C
- Serotype W-135
- Serotype Y
By Sales Channel
- Private
- Public
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Meningococcal Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Meningococcal Vaccine market include Pfizer Inc., Sanofi, Serum Institute Of India Ltd., GSK Plc., Merck & Co. Inc., Walvax Biotechnology Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. MENINGOCOCCAL VACCINE - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Brand
- 3.7.3 Market Attractiveness Analysis By Age Group
- 3.7.4 Market Attractiveness Analysis By Serotype
- 3.7.5 Market Attractiveness Analysis By Sales Channel
- 3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY TYPE
- 5.1. Overview By Type
- 5.2. Historical and Forecast Data
- 5.3. Analysis By Type
- 5.4. Bivalent Historic and Forecast Sales By Regions
- 5.5. Quadrivalent Historic and Forecast Sales By Regions
- 5.6. Others Historic and Forecast Sales By Regions
6. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY BRAND
- 6.1. Overview By Brand
- 6.2. Historical and Forecast Data
- 6.3. Analysis By Brand
- 6.4. Menactra Historic and Forecast Sales By Regions
- 6.5. Menveo Historic and Forecast Sales By Regions
- 6.6. Nimenrix Historic and Forecast Sales By Regions
- 6.7. Trumenba Historic and Forecast Sales By Regions
- 6.8. Bexsero Historic and Forecast Sales By Regions
- 6.9. Others Historic and Forecast Sales By Regions
7. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY AGE GROUP
- 7.1. Overview By Age Group
- 7.2. Historical and Forecast Data
- 7.3. Analysis By Age Group
- 7.4. Infants (0 to 2 years) Historic and Forecast Sales By Regions
- 7.5. Children and Adults (2 years & above) Historic and Forecast Sales By Regions
8. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SEROTYPE
- 8.1. Overview By Serotype
- 8.2. Historical and Forecast Data
- 8.3. Analysis By Serotype
- 8.4. Serotype A Historic and Forecast Sales By Regions
- 8.5. Serotype B Historic and Forecast Sales By Regions
- 8.6. Serotype C Historic and Forecast Sales By Regions
- 8.7. Serotype W-135 Historic and Forecast Sales By Regions
- 8.8. Serotype Y Historic and Forecast Sales By Regions
9. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SALES CHANNEL
- 9.1. Overview By Sales Channel
- 9.2. Historical and Forecast Data
- 9.3. Analysis By Sales Channel
- 9.4. Private Historic and Forecast Sales By Regions
- 9.5. Public Historic and Forecast Sales By Regions
10. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
- 10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
- 10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
- 10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
- 10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE MENINGOCOCCAL VACCINE COMPANIES
- 11.1. Meningococcal Vaccine Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12. COMPANY PROFILES OF MENINGOCOCCAL VACCINE INDUSTRY
- 12.1. Top Companies Market Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Pfizer Inc.
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
- 12.4. Sanofi
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
- 12.5. Serum Institute Of India Ltd.
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
- 12.6. GSK Plc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
- 12.7. Merck & Co. Inc.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
- 12.8. Walvax Biotechnology Co. Ltd
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
